453566-08-0

Basic information

• Product Name: Benzenecarboximidamide,N-hydroxy-3,5-dimethoxy-
• Synonyms: Benzenecarboximidamide,N-hydroxy-3,5-dimethoxy-;Benzenecarboximidamide, N-hydroxy-3,5-dimethoxy- (9CI);N'-Hydroxy-3,5-diMethoxybenziMidaMide
• CAS NO: 453566-08-0
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.20318
• Product Categories: AMIDINE
• Mol File: 453566-08-0.mol

Chemical Properties

• Melting Point: 142-145°
• Appearance: /
• CAS DataBase Reference: Benzenecarboximidamide,N-hydroxy-3,5-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenecarboximidamide,N-hydroxy-3,5-dimethoxy-(453566-08-0)
• EPA Substance Registry System: Benzenecarboximidamide,N-hydroxy-3,5-dimethoxy-(453566-08-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 453566-08-0(Hazardous Substances Data)

Usage

Uses

Used in Chelating Applications:
Benzenecarboximidamide, N-hydroxy-3,5-dimethoxyis used as a chelating agent for its ability to bind metal ions. This property makes it useful in various industrial processes, such as water treatment and metal recovery.
Used in Medicinal Applications:
Benzenecarboximidamide, N-hydroxy-3,5-dimethoxyis used as a potential therapeutic agent for its anti-cancer and anti-inflammatory properties. Its ability to chelate metal ions may contribute to its potential as a treatment for cancer and inflammatory diseases.
Used in Research Applications:
Benzenecarboximidamide, N-hydroxy-3,5-dimethoxyis used as a research compound for studying its potential applications and effects in various fields. Further research is needed to fully understand its potential uses and to develop new applications for this compound.

Upstream product

• 19179-31-8 3,5-dimethoxy-benzonitrile 

Downstream Products

• 453567-35-6 3-(3,5-dimethoxyphenyl)-5-(5-fluoropyrid-2-yl)-1,2,4-oxadiazole 
• 1196463-26-9 C₁₄H₁₈N₂O₆ 

Relevant articles and documents

Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype

We discovered a new chemical class of antiproliferative agents, 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides. SAR-guided optimization of the two distinct terminal fragments yielded a compound with 120 nM potency in an antiproliferative assay. Biologi

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Synthesis, characterization, and antimicrobial activities of clubbed [1,2,4]-oxadiazoles with fluorobenzimidazoles

(Chemical Equation Presented) In this study, a novel series of substituted 4,6-difluoro-2-{2-[3-(substituted-phenyl)-[1,2,4]-oxadiazol-5-yl]-ethyl} -1H-benzo[d]imidazole derivatives were synthesized by condensation of 2,4-difluoro-6-nitrophenyl amine with 3-(substitutedphenyl-[1,2,4]-oxadiazol- 5yl) propionic acid by using 2,4,6-trichlorobenzoyl chloride in the presence of triethyl amine base. The compounds were evaluated for their preliminary in vitro antibacterial activity against Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Salmonella typhosa. The antibacterial data of the tested compounds indicated that most of the synthesized compounds showed moderate activity with reference standard Gentamycin.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors

This paper describes the structure-activity relationships of a new class of cytomegalovirus DNA polymerase inhibitors having two aryl groups joined by an acyloxyamidine linker. Examination of a series of analogues in which the terminal groups are varied r